首页> 外文期刊>Drug Target Insights >Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
【24h】

Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia

机译:与正常对照组和糖尿病重症缺血性患者相比,晚期癌症患者的循环血管内皮生长因子(VEGF)水平

获取原文
           

摘要

Anti-angiogenic therapy is emerging as a valuable tool in the treatment of patients with cancer. As VEGF is a central target in anti-angiogenic therapy, its levels in the circulation might be relevant in selecting tumor types or patients likely to respond to this treatment. Additional VEGF has been recognized as a key factor in the pathogenesis of diabetic retinopathy. Recently anti-angiogenic therapy has been advocated in this situation. We measured VEGF levels in whole blood in 42 patients with high grade (n = 26) and low grade (n = 16) end stage cancer, and in 28 healthy controls and 37 patients with diabetes related vascular disease. Only 2/26 patients in the group of high grade cancer had signifi cantly elevated VEGF levels, 1/16 in the low grade group and 1/28 in the healthy control group. In contrast, in 10/37 diabetic patients the mean VEGF levels were significantly elevated compared to the other groups. The mean level in these diabetic patients was significantly elevated compared to the other groups. These data indicate the limitation of the use of circulating VEGF levels as a potential selection criterion for anti-angiogenic therapy in cancer patients and suggest further studies into its application in the management of diabetic complications.
机译:抗血管生成疗法正在成为治疗癌症患者的重要工具。由于VEGF是抗血管生成治疗的主要靶标,因此其循环水平可能与选择肿瘤类型或可能对此治疗有反应的患者有关。另外的VEGF已经被认为是糖尿病性视网膜病发病机理中的关键因素。最近在这种情况下提倡抗血管生成疗法。我们测量了42例高级别(n = 26)和低级别(n = 16)晚期癌症患者,28例健康对照和37例糖尿病相关血管疾病患者全血中的VEGF水平。高级别癌症组中只有2/26的患者VEGF水平显着升高,低级别组为1/16,健康对照组为1/28。相反,在10/37糖尿病患者中,与其他组相比,平均VEGF水平显着升高。与其他组相比,这些糖尿病患者的平均水平显着升高。这些数据表明使用循环中的VEGF水平作为癌症患者抗血管生成治疗的潜在选择标准的局限性,并建议对其在糖尿病并发症管理中的应用进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号